{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T16:40:34Z","timestamp":1793292034428,"version":"4.5.0"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000921","name":"European Cooperation in Science and Technology","doi-asserted-by":"publisher","award":["CA15135"],"award-info":[{"award-number":["CA15135"]}],"id":[{"id":"10.13039\/501100000921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000921","name":"European Cooperation in Science and Technology","doi-asserted-by":"publisher","award":["CA18124"],"award-info":[{"award-number":["CA18124"]}],"id":[{"id":"10.13039\/501100000921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000921","name":"European Cooperation in Science and Technology","doi-asserted-by":"publisher","award":["CA18133"],"award-info":[{"award-number":["CA18133"]}],"id":[{"id":"10.13039\/501100000921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["GRK2158"],"award-info":[{"award-number":["GRK2158"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["INST208\/664e1"],"award-info":[{"award-number":["INST208\/664e1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.bmc.2021.116462","type":"journal-article","created":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T02:01:04Z","timestamp":1634608864000},"page":"116462","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Histamine H3 receptor antagonists with peptidomimetic (keto)piperazine structures to inhibit A\u03b2 oligomerisation"],"prefix":"10.1016","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9785-2100","authenticated-orcid":false,"given":"Markus","family":"Falkenstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1514-2215","authenticated-orcid":false,"given":"David","family":"Reiner-Link","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5034-7916","authenticated-orcid":false,"given":"Aleksandra","family":"Zivkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0965-3908","authenticated-orcid":false,"given":"Ian","family":"Gering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter","family":"Willbold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3336-1710","authenticated-orcid":false,"given":"Holger","family":"Stark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2021.116462_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.113096","article-title":"Identification of N-phenyl-3-methoxy-4-pyridinones as orally bioavailable H3 receptor antagonists and \u03b2-amyloid aggregation inhibitors for the treatment of Alzheimer\u2019s disease","volume":"212","author":"Zhang","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2021.116462_b0010","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.pneurobio.2018.12.006","article-title":"Comprehensive review of mechanisms of pathogenesis involved in Alzheimer\u2019s disease and potential therapeutic strategies","volume":"174","author":"Sharma","year":"2018","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.bmc.2021.116462_b0015","article-title":"Efficacy of acetylcholinesterase inhibitors in Alzheimer\u2019s disease","volume":"108352","author":"Marucci","year":"2020","journal-title":"J Neuropharm."},{"key":"10.1016\/j.bmc.2021.116462_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.103084","article-title":"Search for multifunctional agents against Alzheimer\u2019s disease among non-imidazole histamine H3 receptor ligands. In vitro and in vivo pharmacological evaluation and computational studies of piperazine derivatives","volume":"90","author":"Jo\u0144czyk","year":"2019","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2021.116462_b0025","unstructured":"Cavazzoni, P. FDA\u2019s Decision to Approve New Treatment for Alzheimer\u2019s Disease | FDA. https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fdas-decision-approve-new-treatment-alzheimers-disease (2021)."},{"key":"10.1016\/j.bmc.2021.116462_b0030","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.pharmthera.2019.04.007","article-title":"Histamine H3 receptor antagonists\/inverse agonists: Where do they go?","volume":"200","author":"Ghamari","year":"2019","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.bmc.2021.116462_b0035","doi-asserted-by":"crossref","first-page":"12765","DOI":"10.1002\/anie.201706072","article-title":"Multitarget-Directed Ligands Combining Cholinesterase and Monoamine Oxidase Inhibition with Histamine H3R Antagonism for Neurodegenerative Diseases","volume":"56","author":"Bautista-Aguilera","year":"2017","journal-title":"Angew Chemie - Int Ed."},{"key":"10.1016\/j.bmc.2021.116462_b0040","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.ejmech.2014.03.014","article-title":"Non-imidazole histamine H3 receptor ligands incorporating antiepileptic moieties","volume":"77","author":"Sadek","year":"2014","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2021.116462_b0045","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1124\/pr.114.010249","article-title":"International union of basic and clinical pharmacology XCVIII. histamine receptors","volume":"67","author":"Panula","year":"2015","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.bmc.2021.116462_b0050","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1248\/bpb.31.2163","article-title":"Histamine H3 Receptor Antagonists Go to Clinics","volume":"31","author":"Sander","year":"2008","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.bmc.2021.116462_b0055","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1080\/13543776.2018.1424135","article-title":"Progress in the development of histamine H3 receptor antagonists\/inverse agonists: a patent review (2013\u20132017)","volume":"28","author":"\u0141a\u017cewska","year":"2018","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/j.bmc.2021.116462_b0060","first-page":"1","article-title":"Selective H3 Antagonist (ABT-239) Differentially Modifies Cognitive Function Under the Impact of Restraint","volume":"14","author":"Trofimiuk","year":"2021","journal-title":"Stress"},{"key":"10.1016\/j.bmc.2021.116462_b0065","doi-asserted-by":"crossref","first-page":"715","DOI":"10.3233\/JAD-190507","article-title":"Developing Effective Alzheimer\u2019s Disease Therapies: Clinical Experience and Future Directions","volume":"71","author":"Elmaleh","year":"2019","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"10.1016\/j.bmc.2021.116462_b0070","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.bcp.2006.10.031","article-title":"Histamine H3 receptor antagonists: From target identification to drug leads","volume":"73","author":"Bonaventure","year":"2007","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bmc.2021.116462_b0075","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1021\/cb400080f","article-title":"Untangling amyloid-beta, tau, and metals in Alzheimer\u2019s disease","volume":"8","author":"Savelieff","year":"2013","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.bmc.2021.116462_b0080","doi-asserted-by":"crossref","DOI":"10.1021\/acs.chemrev.1c00196","article-title":"Amyloid-type Protein Aggregation and Prion-like Properties of Amyloids","author":"Willbold","year":"2021","journal-title":"Chem Rev"},{"key":"10.1016\/j.bmc.2021.116462_b0085","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1016\/j.ijbiomac.2020.07.327","article-title":"Role of tau protein in Alzheimer\u2019s disease: The prime pathological player","volume":"163","author":"Muralidar","year":"2020","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.bmc.2021.116462_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117996","article-title":"Alzheimer\u2019s disease; a review of the pathophysiological basis and therapeutic interventions","volume":"256","author":"Abeysinghe","year":"2020","journal-title":"Life Sci"},{"key":"10.1016\/j.bmc.2021.116462_b0095","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.biopha.2018.12.101","article-title":"Emerging pathways to neurodegeneration: Dissecting the critical molecular mechanisms in Alzheimer\u2019s disease","volume":"111","author":"Tan","year":"2019","journal-title":"Parkinson\u2019s disease Biomed Pharmacother"},{"key":"10.1016\/j.bmc.2021.116462_b0100","doi-asserted-by":"crossref","first-page":"S611","DOI":"10.3233\/JAD-179935","article-title":"Role of Amyloid-\u03b2 and Tau Proteins in Alzheimer\u2019s Disease: Confuting the Amyloid Cascade","volume":"64","author":"Gulisano","year":"2018","journal-title":"J Alzheimer\u2019s Dis"},{"key":"10.1016\/j.bmc.2021.116462_b0105","doi-asserted-by":"crossref","first-page":"4800","DOI":"10.1021\/acschemneuro.9b00458","article-title":"Toward the Mode of Action of the Clinical Stage All-d-Enantiomeric Peptide RD2 on A\u03b242 Aggregation","volume":"10","author":"Zhang","year":"2019","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.bmc.2021.116462_b0110","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1021\/acschemneuro.7b00045","article-title":"Optimization of d -Peptides for A\u03b2 Monomer Binding Specificity Enhances Their Potential to Eliminate Toxic A\u03b2 Oligomers","volume":"8","author":"Klein","year":"2017","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.bmc.2021.116462_b0115","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41582-020-00454-9","article-title":"Aducanumab and the FDA \u2014 where are we now?","volume":"17","author":"Fillit","year":"2021","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.bmc.2021.116462_b0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fnins.2016.00201","article-title":"Multiple targeting approaches on histamine H3receptor antagonists","volume":"10","author":"Khanfar","year":"2016","journal-title":"Front Neurosci"},{"key":"10.1016\/j.bmc.2021.116462_b0125","doi-asserted-by":"crossref","first-page":"2","DOI":"10.2174\/1570159X113116660047","article-title":"Multi-Target-Directed Ligands and other Therapeutic Strategies in the Search of a Real Solution for Alzheimer\u2019s Disease","volume":"12","author":"Agis-Torres","year":"2014","journal-title":"Curr Neuropharmacol"},{"key":"10.1016\/j.bmc.2021.116462_b0130","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1021\/acs.jmedchem.8b00760","article-title":"Polypharmacology by Design: A Medicinal Chemist\u2019s Perspective on Multitargeting Compounds","volume":"62","author":"Proschak","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2021.116462_b0135","doi-asserted-by":"crossref","first-page":"859","DOI":"10.3233\/JAD-180165","article-title":"In vitro potency and preclinical pharmacokinetic comparison of all-d-enantiomeric peptides developed for the treatment of Alzheimer\u2019s disease","volume":"64","author":"Schartmann","year":"2018","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"10.1016\/j.bmc.2021.116462_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104050","article-title":"Design of peptide-based inhibitor agent against amyloid-\u03b2 aggregation : Molecular docking, synthesis and in vitro evaluation","volume":"102","author":"Jokar","year":"2020","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2021.116462_b0145","article-title":"Destabilization of \u03b2-amyloid aggregates by thrombin derived peptide: plausible role of thrombin in neuroprotection","author":"De","year":"2019","journal-title":"FEBS J"},{"key":"10.1016\/j.bmc.2021.116462_b0150","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.46924","article-title":"Structure based inhibitors of amyloid beta core suggest a common interface with Tau","volume":"8","author":"Griner","year":"2019","journal-title":"Elife"},{"key":"10.1016\/j.bmc.2021.116462_b0155","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1021\/cr200398y","article-title":"2,5-diketopiperazines: Synthesis, reactions, medicinal chemistry, and bioactive natural products","volume":"112","author":"Borthwick","year":"2012","journal-title":"Chem Rev"},{"key":"10.1016\/j.bmc.2021.116462_b0160","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/cmdc.201000133","article-title":"Discovery of a class of diketopiperazines as antiprion compounds","volume":"5","author":"Bolognesi","year":"2010","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bmc.2021.116462_b0165","doi-asserted-by":"crossref","first-page":"3942","DOI":"10.1021\/jo060390t","article-title":"Stereoselective synthesis of 3,6-disubstituted-3,6-dihydropyridin-2-ones as potential diketopiperazine mimetics using organocopper-mediated anti-S N2\u2032 reactions and their use in the preparation of low-molecule CXCR4 antagonists","volume":"71","author":"Niida","year":"2006","journal-title":"J Org Chem"},{"key":"10.1016\/j.bmc.2021.116462_b0170","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/nan.12592","article-title":"Invited Review: The role of prion-like mechanisms in neurodegenerative diseases","volume":"46","author":"Jaunmuktane","year":"2020","journal-title":"Neuropathol Appl Neurobiol"},{"key":"10.1016\/j.bmc.2021.116462_b0175","article-title":"Cyclic dipeptides: Biological activities and self-assembled materials","author":"Zhao","year":"2020","journal-title":"Pept Sci"},{"key":"10.1016\/j.bmc.2021.116462_b0180","unstructured":"To Evaluate the Safety, Tolerability and Pharmacokinetics of Oral NNZ-2591 in Healthy Volunteers. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04379869?term=NNZ-2591.&draw=2&rank=1."},{"key":"10.1016\/j.bmc.2021.116462_b0185","doi-asserted-by":"crossref","first-page":"2","DOI":"10.2174\/138955712798868959","article-title":"2,5-Diketopiperazines as Neuroprotective Agents","volume":"12","author":"Cornacchia","year":"2012","journal-title":"Mini-Reviews Med Chem"},{"key":"10.1016\/j.bmc.2021.116462_b0190","article-title":"Structural modifications in the distal, regulatory region of histamine H3 receptor antagonists leading to the identification of a potent anti-obesity agent","author":"Szczepa\u0144ska","year":"2020","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2021.116462_b0195","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1039\/B701677H","article-title":"Amide bond formation: beyond the myth of coupling reagents","volume":"38","author":"Valeur","year":"2009","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.bmc.2021.116462_b0200","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1002\/ange.19790911110","article-title":"Enantioselektive Synthese von \u03b1-Methyl-\u03b1-amino-carbons\u00e4uren durch Alkylierung des Lactimethers von cyclo-(L-Ala-L-Ala)","volume":"91","author":"Sch\u00f6llkopf","year":"1979","journal-title":"Angew Chemie"},{"key":"10.1016\/j.bmc.2021.116462_b0205","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1081\/SCC-120030746","article-title":"Improvements in aldol reactions with diketopiperazines","volume":"34","author":"Gonz\u00e1lez","year":"2004","journal-title":"Synth Commun"},{"key":"10.1016\/j.bmc.2021.116462_b0210","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1021\/jm2009088","article-title":"Synthesis and structure-activity relationship study of antimicrotubule agents phenylahistin derivatives with a didehydropiperazine-2,5-dione structure","volume":"55","author":"Yamazaki","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2021.116462_b0215","article-title":"Analogs of dehydrophenylahistins and their theapeutic use","volume":"US2008\/022","author":"Palladino","year":"2008","journal-title":"United States Pat."},{"key":"10.1016\/j.bmc.2021.116462_b0220","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/psc.446","article-title":"Diketopiperazines in peptide and combinatorial chemistry","volume":"9","author":"Fischer","year":"2003","journal-title":"J Pept Sci"},{"key":"10.1016\/j.bmc.2021.116462_b0225","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.2174\/0929867325666171123203550","article-title":"Histamine H3 Receptor Ligands in the Group of (Homo)piperazine Derivatives","volume":"25","author":"Szczepanska","year":"2018","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.bmc.2021.116462_b0230","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1021\/acschemneuro.8b00132","article-title":"Role of Hydrophobicity and Charge of Amyloid-Beta Oligomer Eliminating d -Peptides in the Interaction with Amyloid-Beta Monomers","volume":"9","author":"Ziehm","year":"2018","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.bmc.2021.116462_b0235","doi-asserted-by":"crossref","first-page":"8743","DOI":"10.1002\/anie.201004437","article-title":"Combining Independent Drug Classes into Superior, Synergistically Acting Hybrid Molecules","volume":"49","author":"M\u00fcller-Schiffmann","year":"2010","journal-title":"Angew Chemie Int Ed"},{"key":"10.1016\/j.bmc.2021.116462_b0240","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1248\/cpb.58.1353","article-title":"Kojic Acid Derivatives as Histamine H3 Receptor Ligands","volume":"58","author":"Sander","year":"2010","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"10.1016\/j.bmc.2021.116462_b0245","doi-asserted-by":"crossref","first-page":"4526","DOI":"10.1021\/acs.jmedchem.5b01767","article-title":"Lead Optimization of 2-Phenylindolylglyoxylyldipeptide Murine Double Minute (MDM)2\/Translocator Protein (TSPO) Dual Inhibitors for the Treatment of Gliomas","volume":"59","author":"Daniele","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2021.116462_b0250","unstructured":"Chambers, M. S. & et al. Bicyclic Heteroaryl-alkylene-(Homo)Piperazinones and Thione Analogues thereof, their preparation, and their use of as selective Agonists of 5HT1 like receptors. United States Pat. US00599841, (1991)."},{"key":"10.1016\/j.bmc.2021.116462_b0255","unstructured":"Carter, D. S. & et al. Arylpiperazine derivatives and uses thereof. United States Pat. US2009\/020, (2009)."},{"key":"10.1016\/j.bmc.2021.116462_b0260","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1021\/jo00834a087","article-title":"A Facile Synthesis of Methanesulfonate Esters","volume":"35","author":"Crossland","year":"1970","journal-title":"J Org Chem"},{"key":"10.1016\/j.bmc.2021.116462_b0265","article-title":"Aryloxyalkylamine deivates as H3 receptor ligands","author":"Best","year":"2004","journal-title":"Int. Appl. Publ. Under Pat. Coop. Treaty WO2004\/037"},{"key":"10.1016\/j.bmc.2021.116462_b0270","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ejphar.2010.12.033","article-title":"Receptor-specific functional efficacies of alkyl imidazoles as dual histamine H3\/H4 receptor ligands","volume":"654","author":"Kottke","year":"2011","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.bmc.2021.116462_b0275","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","article-title":"Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction","volume":"22","author":"Yung-Chi","year":"1973","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bmc.2021.116462_b0280","unstructured":"Bharatam, P. V. Drug Likeness Tool (DruLiTo 1). http:\/\/www.niper.gov.in\/pi_dev_tools\/DruLiToWeb\/DruLiTo_index.html."}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089621004703?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089621004703?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T01:16:03Z","timestamp":1760836563000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089621004703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":56,"alternative-id":["S0968089621004703"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2021.116462","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Histamine H3 receptor antagonists with peptidomimetic (keto)piperazine structures to inhibit A\u03b2 oligomerisation","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2021.116462","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116462"}}